P. Peter Ghoroghchian, M.D., Ph.D.President and CEO at Silagene, Inc.
Paiman Peter Ghoroghchian is currently the President and CEO of Silagene, Inc, joining the firm in August 2020. He previously served as SVP and Head of Therapeutic Development at Repertoire Immune Medicines, Inc. (2019-2020), the Chief Technology Officer at Posedia Therapeutics, Inc (NASDAQ: PSTX) (2016-2019), and the Chief Scientific Officer of Vindico NanoBioTechnology (2009-2016). Dr. Ghoroghchian obtained his B.S. in chemical engineering from MIT, followed by Ph.D. and M.D. degrees from the University of Pennsylvania. After medical school, he completed an internship and residency training in Internal Medicine at the Brigham and Women’s Hospital, as well as fellowship training in hematology and medical oncology at the Dana-Farber Cancer Institute and the Massachusetts General Hospital. Dr. Ghoroghchian thereafter served as an attending physician in the Susan F. Smith Center for Women’s Cancers at the Dana-Farber Cancer Institute and as an instructor at Harvard Medical School. He concurrently held the position as the Charles W. and Jennifer C. Johnson clinical investigator in the Koch Institute for Integrative Cancer Research at MIT, where he directed an independent research laboratory that developed technologies for biomedical imaging, drug delivery and gene editing. Dr. Ghoroghchian has also overseen research efforts at PhenoTech Inc., and other firms.